Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.

Asbach B, Kibler KV, Köstler J, Perdiguero B, Yates NL, Stanfield-Oakley S, Tomaras GD, Kao SF, Foulds KE, Roederer M, Seaman MS, Montefiori DC, Parks R, Ferrari G, Forthal DN, Phogat S, Tartaglia J, Barnett SW, Self SG, Gottardo R, Cristillo AD, Weiss DE, Galmin L, Ding S, Heeney JL, Esteban M, Jacobs BL, Pantaleo G, Wagner R.

J Virol. 2019 Jan 17;93(3). pii: e01529-18. doi: 10.1128/JVI.01529-18. Print 2019 Feb 1.

PMID:
30429343
2.

Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.

Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, Mabwe S, Makhethe L, Erasmus M, Toefy A, Mulenga H, Hanekom WA, Self SG, Bekker LG, Ryall R, Gurunathan S, DiazGranados CA, Andersen P, Kromann I, Evans T, Ellis RD, Landry B, Hokey DA, Hopkins R, Ginsberg AM, Scriba TJ, Hatherill M; C-040-404 Study Team.

N Engl J Med. 2018 Jul 12;379(2):138-149. doi: 10.1056/NEJMoa1714021.

3.

Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.

Moodie Z, Juraska M, Huang Y, Zhuang Y, Fong Y, Carpp LN, Self SG, Chambonneau L, Small R, Jackson N, Noriega F, Gilbert PB.

J Infect Dis. 2018 Feb 14;217(5):742-753. doi: 10.1093/infdis/jix609.

PMID:
29194547
4.

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.

García-Arriaza J, Perdiguero B, Heeney JL, Seaman MS, Montefiori DC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Self SG, Borate B, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Lee C, Kibler KV, Jacobs BL, Wagner R, Ding S, Pantaleo G, Esteban M.

J Virol. 2017 Apr 13;91(9). pii: e02182-16. doi: 10.1128/JVI.02182-16. Print 2017 May 1.

5.

Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.

Asbach B, Kliche A, Köstler J, Perdiguero B, Esteban M, Jacobs BL, Montefiori DC, LaBranche CC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Landucci G, Forthal DN, Seaman MS, Hawkins N, Self SG, Sato A, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Francis J, Galmin L, Ding S, Heeney JL, Pantaleo G, Wagner R.

J Virol. 2016 Mar 28;90(8):4133-4149. doi: 10.1128/JVI.03135-15. Print 2016 Apr.

6.

Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.

Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, Li F, Hertz T, Self SG, Friedrich D, Frahm N, Liao HX, Montefiori DC, Tomaras GD, McElrath MJ, Hural J, Graham BS, Jin X; HVTN 083 Study Group and the NIAID HVTN.

J Infect Dis. 2016 Feb 15;213(4):541-50. doi: 10.1093/infdis/jiv496. Epub 2015 Oct 15.

7.

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders.

Janes H, Herbeck JT, Tovanabutra S, Thomas R, Frahm N, Duerr A, Hural J, Corey L, Self SG, Buchbinder SP, McElrath MJ, O'Connell RJ, Paris RM, Rerks-Ngarm S, Nitayaphan S, Pitisuttihum P, Kaewkungwal J, Robb ML, Michael NL, Mullins JI, Kim JH, Gilbert PB, Rolland M.

Nat Med. 2015 Oct;21(10):1139-41. doi: 10.1038/nm.3932. Epub 2015 Aug 31.

8.

Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus.

Li X, Paulson TG, Galipeau PC, Sanchez CA, Liu K, Kuhner MK, Maley CC, Self SG, Vaughan TL, Reid BJ, Blount PL.

Cancer Prev Res (Phila). 2015 Sep;8(9):845-56. doi: 10.1158/1940-6207.CAPR-15-0130. Epub 2015 Jun 30.

9.

Levels of PCDDs, PCDFs and dl-PCBs in the blood of childbearing-aged women living in the vicinity of a chemical plant in Tianjin: a primary study.

Chen X, Chen JS, Zhang L, Li JG, Yao L, Self SG, Sun X, Tang NJ.

Chemosphere. 2015 Jan;118:1-4. doi: 10.1016/j.chemosphere.2014.05.026. Epub 2014 Jun 7.

PMID:
25433396
10.

Tuberculosis vaccines and prevention of infection.

Hawn TR, Day TA, Scriba TJ, Hatherill M, Hanekom WA, Evans TG, Churchyard GJ, Kublin JG, Bekker LG, Self SG.

Microbiol Mol Biol Rev. 2014 Dec;78(4):650-71. doi: 10.1128/MMBR.00021-14. Review.

11.

Finding gene clusters for a replicated time course study.

Qin LX, Breeden L, Self SG.

BMC Res Notes. 2014 Jan 24;7:60. doi: 10.1186/1756-0500-7-60.

12.

Advancing the high throughput identification of liver fibrosis protein signatures using multiplexed ion mobility spectrometry.

Baker ES, Burnum-Johnson KE, Jacobs JM, Diamond DL, Brown RN, Ibrahim YM, Orton DJ, Piehowski PD, Purdy DE, Moore RJ, Danielson WF 3rd, Monroe ME, Crowell KL, Slysz GW, Gritsenko MA, Sandoval JD, Lamarche BL, Matzke MM, Webb-Robertson BJ, Simons BC, McMahon BJ, Bhattacharya R, Perkins JD, Carithers RL Jr, Strom S, Self SG, Katze MG, Anderson GA, Smith RD.

Mol Cell Proteomics. 2014 Apr;13(4):1119-27. doi: 10.1074/mcp.M113.034595. Epub 2014 Jan 8.

13.

Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus.

Li X, Galipeau PC, Paulson TG, Sanchez CA, Arnaudo J, Liu K, Sather CL, Kostadinov RL, Odze RD, Kuhner MK, Maley CC, Self SG, Vaughan TL, Blount PL, Reid BJ.

Cancer Prev Res (Phila). 2014 Jan;7(1):114-27. doi: 10.1158/1940-6207.CAPR-13-0289. Epub 2013 Nov 19.

14.

HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.

Hertz T, Ahmed H, Friedrich DP, Casimiro DR, Self SG, Corey L, McElrath MJ, Buchbinder S, Horton H, Frahm N, Robertson MN, Graham BS, Gilbert P.

PLoS Pathog. 2013;9(6):e1003404. doi: 10.1371/journal.ppat.1003404. Epub 2013 Jun 20.

15.

Implications of Age-Dependent Immune Responses to Enterovirus 71 Infection for Disease Pathogenesis and Vaccine Design.

Gantt S, Yao L, Kollmann TR, Casper C, Zhang J, Self SG.

J Pediatric Infect Dis Soc. 2013 Jun;2(2):162-70. doi: 10.1093/jpids/pit017. Epub 2013 Apr 26. Review.

PMID:
26619463
16.

HIV Vaccine Trials Network: activities and achievements of the first decade and beyond.

Kublin JG, Morgan CA, Day TA, Gilbert PB, Self SG, McElrath MJ, Corey L.

Clin Investig (Lond). 2012 Mar;2(3):245-254.

17.

A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens.

Gilbert PB, Grove D, Gabriel E, Huang Y, Gray G, Hammer SM, Buchbinder SP, Kublin J, Corey L, Self SG.

Stat Commun Infect Dis. 2011 Oct;3(1). pii: 1037.

18.

Optimization and qualification of an 8-color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre-clinical vaccine studies.

Donaldson MM, Kao SF, Eslamizar L, Gee C, Koopman G, Lifton M, Schmitz JE, Sylwester AW, Wilson A, Hawkins N, Self SG, Roederer M, Foulds KE.

J Immunol Methods. 2012 Dec 14;386(1-2):10-21. doi: 10.1016/j.jim.2012.08.011. Epub 2012 Aug 28.

19.

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, Greene K, Gao H, LaBranche CC, Andrews C, Polonis VR, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Self SG, Berman PW, Francis D, Sinangil F, Lee C, Tartaglia J, Robb ML, Haynes BF, Michael NL, Kim JH.

J Infect Dis. 2012 Aug 1;206(3):431-41. doi: 10.1093/infdis/jis367. Epub 2012 May 25.

20.

Statistical approaches to analyzing HIV-1 neutralizing antibody assay data.

Yu X, Gilbert PB, Hioe CE, Zolla-Pazner S, Self SG.

Stat Biopharm Res. 2012 Jan 1;4(1):1-13.

21.

Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys.

Kaufman DR, Li F, Cruz AN, Self SG, Barouch DH.

Vaccine. 2012 Jan 11;30(3):506-9. doi: 10.1016/j.vaccine.2011.11.079. Epub 2011 Nov 29.

22.

Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study.

Li F, Finnefrock AC, Dubey SA, Korber BT, Szinger J, Cole S, McElrath MJ, Shiver JW, Casimiro DR, Corey L, Self SG.

PLoS One. 2011;6(6):e20479. doi: 10.1371/journal.pone.0020479. Epub 2011 Jun 10.

23.

Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.

Rolland M, Tovanabutra S, deCamp AC, Frahm N, Gilbert PB, Sanders-Buell E, Heath L, Magaret CA, Bose M, Bradfield A, O'Sullivan A, Crossler J, Jones T, Nau M, Wong K, Zhao H, Raugi DN, Sorensen S, Stoddard JN, Maust BS, Deng W, Hural J, Dubey S, Michael NL, Shiver J, Corey L, Li F, Self SG, Kim J, Buchbinder S, Casimiro DR, Robertson MN, Duerr A, McElrath MJ, McCutchan FE, Mullins JI.

Nat Med. 2011 Mar;17(3):366-71. doi: 10.1038/nm.2316. Epub 2011 Feb 27.

24.

HIV fragment gag vaccine induces broader T cell response in mice.

Liu Y, Li F, Liu Y, Hong K, Meng X, Chen J, Zhang Z, Huo Z, Sun M, Self SG, Shao Y.

Vaccine. 2011 Mar 21;29(14):2582-9. doi: 10.1016/j.vaccine.2011.01.049. Epub 2011 Feb 1.

PMID:
21292005
25.

Equivalence of ELISpot assays demonstrated between major HIV network laboratories.

Gill DK, Huang Y, Levine GL, Sambor A, Carter DK, Sato A, Kopycinski J, Hayes P, Hahn B, Birungi J, Tarragona-Fiol T, Wan H, Randles M, Cooper AR, Ssemaganda A, Clark L, Kaleebu P, Self SG, Koup R, Wood B, McElrath MJ, Cox JH, Hural J, Gilmour J.

PLoS One. 2010 Dec 14;5(12):e14330. doi: 10.1371/journal.pone.0014330.

26.

Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells.

Corbett NP, Blimkie D, Ho KC, Cai B, Sutherland DP, Kallos A, Crabtree J, Rein-Weston A, Lavoie PM, Turvey SE, Hawkins NR, Self SG, Wilson CB, Hajjar AM, Fortuno ES 3rd, Kollmann TR.

PLoS One. 2010 Nov 30;5(11):e15041. doi: 10.1371/journal.pone.0015041.

27.

Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.

Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D'Souza P, Rodriguez-Chavez IR, DeCamp A, Giganti M, Berman PW, Self SG, Montefiori DC.

J Infect Dis. 2010 Aug 15;202(4):595-605. doi: 10.1086/654816.

28.

Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection.

Ribeiro RM, Qin L, Chavez LL, Li D, Self SG, Perelson AS.

J Virol. 2010 Jun;84(12):6096-102. doi: 10.1128/JVI.00127-10. Epub 2010 Mar 31.

29.
31.

Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.

Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbert PB, Self SG, Korber BT, Montefiori DC, Mascola JR.

J Virol. 2010 Feb;84(3):1439-52. doi: 10.1128/JVI.02108-09. Epub 2009 Nov 25.

32.

Neonatal innate TLR-mediated responses are distinct from those of adults.

Kollmann TR, Crabtree J, Rein-Weston A, Blimkie D, Thommai F, Wang XY, Lavoie PM, Furlong J, Fortuno ES 3rd, Hajjar AM, Hawkins NR, Self SG, Wilson CB.

J Immunol. 2009 Dec 1;183(11):7150-60. doi: 10.4049/jimmunol.0901481. Epub 2009 Nov 16.

33.

Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments.

Hudgens MG, Gilbert PB, Mascola JR, Wu CD, Barouch DH, Self SG.

J Infect Dis. 2009 Aug 15;200(4):609-13. doi: 10.1086/600891.

34.

Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys.

Barouch DH, Liu J, Lynch DM, O'Brien KL, La Porte A, Simmons NL, Riggs AM, Clark S, Abbink P, Montefiori DC, Landucci G, Forthal DN, Self SG, Carville A, Mansfield K, Goudsmit J.

J Virol. 2009 Sep;83(18):9584-90. doi: 10.1128/JVI.00821-09. Epub 2009 Jun 24.

35.

Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections.

Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, Lebedeva M, DeCamp A, Li D, Grove D, Self SG, Borrow P.

J Virol. 2009 Apr;83(8):3719-33. doi: 10.1128/JVI.01844-08. Epub 2009 Jan 28.

36.

Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'.

Gilbert PB, Qin L, Self SG.

Stat Med. 2009 Feb 15;28(4):716-9. doi: 10.1002/sim.3503. No abstract available.

37.

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR; Step Study Protocol Team.

Lancet. 2008 Nov 29;372(9653):1894-1905. doi: 10.1016/S0140-6736(08)61592-5. Epub 2008 Nov 13.

38.

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.

Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks CB, Liao HX, Self SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, Karim SS, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF.

J Virol. 2008 Dec;82(24):12449-63. doi: 10.1128/JVI.01708-08. Epub 2008 Oct 8.

39.

Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials.

Shulman N, Bellew M, Snelling G, Carter D, Huang Y, Li H, Self SG, McElrath MJ, De Rosa SC.

Cytometry A. 2008 Sep;73(9):847-56. doi: 10.1002/cyto.a.20600.

40.

Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design.

Gasper-Smith N, Crossman DM, Whitesides JF, Mensali N, Ottinger JS, Plonk SG, Moody MA, Ferrari G, Weinhold KJ, Miller SE, Reich CF 3rd, Qin L, Self SG, Shaw GM, Denny TN, Jones LE, Pisetsky DS, Haynes BF.

J Virol. 2008 Aug;82(15):7700-10. doi: 10.1128/JVI.00605-08. Epub 2008 May 28.

41.

Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa.

Abu-Raddad LJ, Magaret AS, Celum C, Wald A, Longini IM Jr, Self SG, Corey L.

PLoS One. 2008 May 21;3(5):e2230. doi: 10.1371/journal.pone.0002230.

42.

Towards prediction of degenerate CTL epitope recognition.

Li F, McKenney DM, Malhotra U, Crimi C, Nolin J, Corey L, McElrath JM, Newman MJ, Self SG.

Hum Vaccin. 2008 Mar-Apr;4(2):115-21. Epub 2007 Oct 26.

PMID:
18382130
43.

Identifying trait clusters by linkage profiles: application in genetical genomics.

Sampson JN, Self SG.

Bioinformatics. 2008 Apr 1;24(7):958-64. doi: 10.1093/bioinformatics/btn064. Epub 2008 Feb 29.

PMID:
18310620
44.

Direct inference of SNP heterozygosity rates and resolution of LOH detection.

Li X, Self SG, Galipeau PC, Paulson TG, Reid BJ.

PLoS Comput Biol. 2007 Nov;3(11):e244.

45.

Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads.

Jaspan HB, Cunningham CK, Tucker TJ, Wright PF, Self SG, Sheets RL, Rogers AS, Bekker LG, Wilson CM, Duerr A, Wasserheit JN; HIV Vaccine Adolescent Trials Working Group.

J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):86-92.

PMID:
17984759
46.
47.

A framework for assessing immunological correlates of protection in vaccine trials.

Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG.

J Infect Dis. 2007 Nov 1;196(9):1304-12. Epub 2007 Oct 2.

PMID:
17922394
48.

HIV-1 CTL-based vaccine immunogen selection: antigen diversity and cellular response features.

Li F, Horton H, Gilbert PB, McElrath JM, Corey L, Self SG.

Curr HIV Res. 2007 Jan;5(1):97-107.

PMID:
17266561
49.
50.

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.

Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, Weinhold KJ, Montefiori DC, Ferrari G, Horton H, Tomaras GD, Gurunathan S, Baglyos L, Frey SE, Mulligan MJ, Harro CD, Buchbinder SP, Baden LR, Blattner WA, Koblin BA, Corey L; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network.

J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):203-12.

Supplemental Content

Support Center